



Selfdiagnostics Multitest - the only affordable multiplexed rapid molecular test portfolio, allowing fast confirmative results at point of care.

COVID-19, Chlamydia Trachomatis, Neisseria Gonorrhoea tests available.

Selfdiagnostics Multitest COVID-19 rapid molecular test

Sensitivity 97%/specificity 100% compared to FDA
EUA approved PCR

Unlimited throughput
of tests within 45
minutes

Applicable in every
point-of-care
setting



No
instruments



45 minutes



Use an unlimited
number of tests
simultaneously



Testing services
and certificates



Production and
workplaces



Hospitals and
emergency rooms



Nursing
homes



Schools and
kindergartens

Selfdiagnostics Multitest COVID-19 bridges antigen testing and laboratory PCR testing

Although rapid antigen tests are quick and convenient and can be used outside the laboratory, their sensitivity and specificity is generally lower than that of the PCR test. This is why the confirmatory NAAT (PCR) test is advised. PCR tests do have high sensitivity and specificity, but their turnaround time ranges from hours to days, they are labour intensive and require laboratory infrastructure and skilled personnel (source: WHO/FIND SARS-CoV-2 antigen-detecting rapid diagnostic tests implementation guide).

Selfdiagnostics Multitest COVID-19 – the rapid molecular NAAT test combines the ease of use of rapid tests and the diagnostic accuracy of laboratory PCR.

PCR-LEVEL TESTING WITHOUT INVESTMENT





Very straightforward single-use test requires no investment in instruments or infrastructure. No maintenance contracts. No calibration.

UNLIMITED THROUGHPUT

Each test runs independently – there is no need to wait for an instrument to finish the previous test.

EASY AND PORTABLE

Just swab and test – does not require any training. The single-use test is just slightly larger than a credit card. Room temperature stable.



Selfdiagnostics Multitest platform – an innovative tool for launching a family of rapid molecular tests.

So far, rapid tests have needed a confirmatory laboratory test. For the first time in history, molecular rapid tests enable diagnosis confirmation without a repeat laboratory test, giving doctors the possibility to start treatment immediately.

Multitest long-term advantages:

MASS-PRODUCIBLE

Intentionally simple and minimal component design for cost efficient mass production. Modular production line enables fast production scale-up.

MULTIPLEXED

Able to differentiate up to four different organism's RNA or DNA from one sample in a single run. Duplex panel test – Selfdiagnostics STD Multitest CT/NG is in our portfolio.

EXPANDABLE

Has proven multi-sample capability. Tests from swab and urine samples are ready. Expandable to detect from blood, soil and water.



Selfdiagnostics Multitest COVID-19 is a good fit for the following settings:



Hospitals to increase rapid PCR testing in emergency departments and on wards immediately without investment in additional instruments.



Testing service providers to offer rapid PCR results for certificates or immediate diagnostics decisions.



Small clinics to have modern PCR testing results without the need to set up a big lab or outsource a PCR testing service.



Companies to keep production facilities open by discovering infected individuals reliably and rapidly.

About Selfdiagnostics in molecular diagnostics

Selfdiagnostics was founded by a physicist, a chemist and a molecular biologist. Their aim was to bring accurate and fast diagnostics closer to the people who are suffering and can't get a cure just because accurate diagnostics was either too late or altogether unavailable.

Since then, the Selfdiagnostics team of scientists and engineers has created a platform for multiplex single-use molecular diagnostics tests, which can be used for every infection, so that doctors are able to make accurate and fast diagnostic decisions anywhere and at any time.

Key facts:

- Thanks to partnerships with Fraunhofer Institute for Cell Therapy and Immunology (IZI), Dresden University of Technology, TalTech and the University of Tartu, Selfdiagnostics has access to top European virology labs for continued R&D and validation.
- In cooperation with Saxonian Development Bank (SAB), Selfdiagnostics fills the German government order to develop and manufacture innovative testing technology.
- Multiplex platform and tests are developed and manufactured in Germany.
- Multiplex platform is covered by two patent families.
- R&D, validation and manufacturing expertise is kept in-house to allow the continuous improvement of the testing platform and the addition of new tests.
- Selfdiagnostics is an ISO 13485 certified company.

Following first commercial availability under the CE Mark in select markets, Selfdiagnostics plans CE IVDR and FDA clearance for the Multitest COVID-19 and Multitest CT/NG in other global markets throughout 2022.



Selfdiagnostics Deutschland GmbH
Deutscher Platz 5 d
04103 Leipzig, Germany
www.selfdiagnostics.eu